{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:04:01Z","timestamp":1785416641574,"version":"3.56.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jtct.2026.04.003","type":"journal-article","created":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T15:24:11Z","timestamp":1775316251000},"page":"950.e1-950.e16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Outcomes of Salvage Therapy after Early-Line CD19 Chimeric Antigen Receptor T-Cell Failure in Large B-Cell Lymphoma"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9499-8999","authenticated-orcid":false,"given":"Silvia","family":"Escribano Serrat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0456-5618","authenticated-orcid":false,"given":"Andrew","family":"Ip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6934-4619","authenticated-orcid":false,"given":"Jaime","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Gomez-Llobell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrun","family":"Einarsdottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronit","family":"Marcus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4566-0570","authenticated-orcid":false,"given":"Ori Ben","family":"Valid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noa Golan","family":"Accav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matar Ben","family":"Yehuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yara Abu","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimrit","family":"Ringeltein-Harlev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8582-4572","authenticated-orcid":false,"given":"Uri","family":"Greenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Goy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7888-1715","authenticated-orcid":false,"given":"Teng","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Geva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efrat","family":"Luttwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Scordo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Lia","family":"Palomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8153-1820","authenticated-orcid":false,"given":"Jennifer K.","family":"Lue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae H.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiko","family":"Sch\u00f6der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burcin Agridag","family":"Ucpinar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunjan","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3905-0251","authenticated-orcid":false,"given":"Kai","family":"Rejeski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofrat","family":"Beyar-Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Avigdor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-4571","authenticated-orcid":false,"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9827-8032","authenticated-orcid":false,"given":"Roni","family":"Shouval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.jtct.2026.04.003_bib0001","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jtct.2026.04.003_bib0002","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2026.04.003_bib0003","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.jtct.2026.04.003_bib0004","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood.2022018295","article-title":"Post-CAR relapse in DLBCL: a fork in the road","volume":"140","author":"Abramson","year":"2022","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.jtct.2026.04.003_bib0005","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.1016\/j.jtct.2026.04.003_bib0006","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.20.01467","article-title":"Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy","volume":"38","author":"Cappell","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jtct.2026.04.003_bib0007","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/bjh.18209","article-title":"A national service for delivering CD19 CAR-Tin large B-cell lymphoma \u2013 the UK real-world experience","volume":"198","author":"Kuhnl","year":"2022","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.jtct.2026.04.003_bib0008","doi-asserted-by":"crossref","first-page":"581.e1","DOI":"10.1016\/j.jtct.2022.05.026","article-title":"Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States","volume":"28","author":"Jacobson","year":"2022","journal-title":"Transplant Cell Ther."},{"issue":"24","key":"10.1016\/j.jtct.2026.04.003_bib0009","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1182\/blood.2022016945","article-title":"Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis","volume":"140","author":"Di Blasi","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2026.04.003_bib0010","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/s41409-025-02519-z","article-title":"Treatment failure patterns in early versus late introduction of CAR T-cell therapy in large B-cell lymphoma","volume":"60","author":"Corona","year":"2025","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jtct.2026.04.003_bib0011","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jtct.2022.05.043","article-title":"ASTCT Committee on Practice Guidelines Survey on Evaluation & Management of Diffuse Large B-cell lymphoma after failure of chimeric antigen receptor T cell therapy (CAR-T) therapy","volume":"28","author":"Ahmed","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.jtct.2026.04.003_bib0012","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41375-022-01739-2","article-title":"Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma","volume":"37","author":"Alarcon Tomas","year":"2023","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.jtct.2026.04.003_bib0013","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"10343","key":"10.1016\/j.jtct.2026.04.003_bib0014","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet Lond Engl"},{"issue":"9","key":"10.1016\/j.jtct.2026.04.003_bib0015","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jtct.2022.06.019","article-title":"Role of CD19 chimeric antigen receptor t cells in second-line large B cell lymphoma: lessons from phase 3 trials. An expert panel opinion from the American Society for Transplantation and Cellular Therapy","volume":"28","author":"Perales","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"10.1016\/j.jtct.2026.04.003_bib0016","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/14712598.2024.2354371","article-title":"Meta-analysis of response rates to first-line salvage treatment after CAR-T therapy failure in large B-cell lymphoma patients","volume":"24","author":"Tomasik","year":"2024","journal-title":"Expert Opin Biol Ther"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2026.04.003_bib0017","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1182\/blood-2022-169219","article-title":"Salvage treatment with novel agents is preferable to standard chemotherapy in patients with large B-cell lymphoma progressing after chimeric antigen receptor T-cell therapy","volume":"140","author":"Iacoboni","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2026.04.003_bib0018","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1182\/blood.2023023789","article-title":"The current landscape of frontline large B-cell lymphoma trials","volume":"145","author":"Qualls","year":"2025","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.jtct.2026.04.003_bib0019","doi-asserted-by":"crossref","first-page":"5371","DOI":"10.1182\/bloodadvances.2024013726","article-title":"Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy","volume":"8","author":"Camus","year":"2024","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.jtct.2026.04.003_bib0020","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.jtct.2023.09.008","article-title":"Long-term survivors after failure of chimeric antigen receptor T cell therapy for large B cell lymphoma: a role for allogeneic hematopoietic cell transplantation? A German lymphoma alliance and German registry for stem cell transplantation analysis","volume":"29","author":"Derigs","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.jtct.2026.04.003_bib0021","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jtct.2026.04.003_bib0022","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.jtct.2026.04.003_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"issue":"27","key":"10.1016\/j.jtct.2026.04.003_bib0024","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jtct.2026.04.003_bib0025","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"10254","key":"10.1016\/j.jtct.2026.04.003_bib0026","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet Lond Engl"},{"issue":"15","key":"10.1016\/j.jtct.2026.04.003_bib0027","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1182\/bloodadvances.2024015719","article-title":"Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed\/refractory large B-cell lymphoma","volume":"9","author":"Shumilov","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2026.04.003_bib0028","article-title":"Management considerations for patients with primary refractory and early relapsed diffuse large B-cell lymphoma","volume":"43","author":"Duarte","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"6","key":"10.1016\/j.jtct.2026.04.003_bib0029","doi-asserted-by":"crossref","first-page":"342.e1","DOI":"10.1016\/j.jtct.2022.02.021","article-title":"Assessment of salvage regimens post-chimeric antigen receptor T cell therapy for patients with diffuse large B cell lymphoma","volume":"28","author":"Sigmund","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"22","key":"10.1016\/j.jtct.2026.04.003_bib0030","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv"},{"issue":"18","key":"10.1016\/j.jtct.2026.04.003_bib0031","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1182\/blood.2025029117","article-title":"Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab","volume":"146","author":"Brooks","year":"2025","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jtct.2026.04.003_bib0032","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/s43018-025-00941-2","article-title":"Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study","volume":"6","author":"Cartron","year":"2025","journal-title":"Nat Cancer."},{"key":"10.1016\/j.jtct.2026.04.003_bib0033","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1404351","article-title":"Late events after anti-CD19 CAR T-cell therapy for relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"14","author":"Cordeiro","year":"2024","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.jtct.2026.04.003_bib0034","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.3390\/cancers14061501","article-title":"Cytopenia after CAR-T cell therapy\u2014a brief review of a complex problem","volume":"14","author":"Sharma","year":"2022","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.jtct.2026.04.003_bib0035","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1158\/2643-3230.BCD-24-0163","article-title":"Dynamics of immune reconstitution and impact on outcomes across CAR-T cell products in large B-cell lymphoma","volume":"6","author":"Luan","year":"2025","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"10.1016\/j.jtct.2026.04.003_bib0036","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70062","article-title":"Prognostic significance of immune reconstitution following CD19 CAR T-cell therapy for relapsed\/refractory B-cell lymphoma","volume":"9","author":"Stock","year":"2025","journal-title":"HemaSphere"},{"issue":"5","key":"10.1016\/j.jtct.2026.04.003_bib0037","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/bloodadvances.2025017766","article-title":"Prognostic value of inflammation-based scores in patients with R\/R LBCL treated with CD3\u00d7CD20 bispecific T-cell engagers","volume":"10","author":"Magno","year":"2026","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2026.04.003_bib0038","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2025-3733","article-title":"Outcomes and treatment patterns of patients with primary mediastinal B-cell lymphoma after CAR-T cell therapy failure: a DESCAR-T analysis","volume":"146","author":"Galtier","year":"2025","journal-title":"Blood"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726002630?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726002630?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:36:01Z","timestamp":1785414961000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726002630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2666636726002630"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.04.003","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of Salvage Therapy after Early-Line CD19 Chimeric Antigen Receptor T-Cell Failure in Large B-Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}